Genocea Biosciences, Inc.
GNCAQ
$0.00
$0.000.00%
OTC PK
03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | |
---|---|---|---|---|---|
Net Income | -20.32% | -266.65% | 15.98% | 64.02% | 20.03% |
Total Depreciation and Amortization | 236.99% | -173.55% | 7.01% | -2.62% | 215.81% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 30.64% | 110.44% | 23.00% | -16,641.07% | -101.56% |
Change in Net Operating Assets | -160.81% | 210.59% | -132.68% | 481.36% | -149.80% |
Cash from Operations | -36.96% | 2.24% | -8.07% | 15.18% | -28.53% |
Capital Expenditure | -2.78% | -76.42% | 25.77% | 35.62% | 19.11% |
Sale of Property, Plant, and Equipment | 46.67% | -- | -- | -100.00% | 1,525.00% |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -2.07% | -73.58% | 25.77% | 31.61% | 23.63% |
Total Debt Issued | -- | -- | -- | -100.00% | -- |
Total Debt Repaid | 0.00% | -- | -- | 100.00% | -60,695.65% |
Issuance of Common Stock | -74.46% | 279.70% | -92.86% | 37.58% | 27.93% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | 100.00% | -- |
Cash from Financing | -425.66% | -33.58% | -92.86% | 1,982.15% | -109.42% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -44.65% | -2.34% | -103.89% | 58.96% | -74.82% |